OrlandBio (CEO Donggeun Han) announced on April 24 that, in collaboration with Professor Dongyul Lee’s research team at CHA University and Dr. Daseul Kim of Harvard Medical School in the United States, it has developed a therapeutic technology capable of restoring ovarian function diminished by various causes.
The research team explained that they developed a "stem cell-loaded anti-inflammatory and antioxidant sponge-type scaffold," which incorporates polydeoxyribonucleotide (PDRN) and melatonin into a biodegradable polymer material. According to the researchers, this scaffold creates an environment similar to ovarian tissue, promoting healthy blood vessel growth and reducing harmful reactive oxygen species. Additionally, by including stem cells (hESC-MPC), the scaffold further aided the recovery of ovarian tissue. The researchers stated, "This technology restored ovarian function and normalized female hormone levels in experimental mice that had entered menopause due to cancer therapy," and added, "It also resulted in successful healthy births." This study was published in the biomaterials journal AHM (Advanced Healthcare Materials) on April 14.
Founded in October last year, OrlandBio is engaged in research and development of convergent medical device products based on advanced biomaterials. The company recently secured a 300 million won investment from Genexis Co., Ltd., a global accelerator and TIPS operator. CEO Donggeun Han, formerly a professor in the Department of Biomedical Science at CHA University, was appointed as CEO in March. Han is scheduled to hold both his retirement ceremony as a professor and the company's opening ceremony at Uiwang Smart City Quantum on April 25.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
